Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
Open accessThe DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSC) are a diverse population of immature myeloid cells that have potent immune-suppressive activity. Studies in both mice and humans have demonstrated that MDSC accumulate in most individuals with cancer, where they promote tumor progression, inhibit antitumor immunity, and are an obstacle to many cancer immunotherapies. As a result, there has been intense interest in understanding the mechanisms and in situ conditions that regulate and sustain MDSC, and the mechanisms MDSC use to promote tumor progression. This article reviews the characterization of MDSC and how they are distinguished from neutrophils, describes the suppressive mechanisms used by MDSC to mediate their effects, and explains the role of proinflammatory mediators and the tumor microenvironment in driving MDSC accumulation, suppressive potency, and survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preclinical models, both of these innate immune cell types aid tumor growth and metastasis through their secretion of factors that suppress antitumor immune responses, especially those of CD8 + T cells and NK cells (166, 167).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 13×
“In contrast to STAT3, which promotes MDSC accumulation, IRF8 deters PMN-MDSC accumulation.”
BackgroundInfluentialCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Self-citationPolarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751 · cited 1×
“Because there has been considerable discussion about the nomenclature, phenotype, and function of this cell population, an international group of investigators in the field recently recommended nomenclature and characterization standards for MDSC (15).”
BackgroundSelf-citationThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736 · cited 1×
“driving force for MDSC, and the hypothesis that one of the mechanisms by which inflammation drives cancer risk and tumor progression is through the suppression of antitumor immunity (47).”
Self-citationHuang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., & Van Ginderachter, J. A. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234 · cited 1×
“Initial studies identified twomajor subtypes ofMDSC inmice, monocytic MDSC (M-MDSC) and granulocytic polymorphonuclear MDSC (PMN-MDSC) (17).”
BackgroundAltered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,174 · cited 1×
“Peroxynitrite released by MDSC nitrates the TcR and MHC class I, thereby perturbing T cell recognition and preventing both T cell activation and T cell function (101, 102).”
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148 · cited 1×
“which have a similar function, were reported in the 1980s (2–5), and reviewed previously (6).”
BackgroundYang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140 · cited 5×
“Vascular endothelial growth factor (VEGF) is predominantly thought of as a growth factor that supports tumor progression by promoting neoangiogenesis.”
BackgroundInfluentialGabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048
Chalmin, F., Ladoire, S., Mignot, G., Vincent, J., Bruchard, M., Remy-Martin, J.-P., Boireau, W., Rouleau, A., Simon, B., Lanneau, D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40483 · Cited by 998 · cited 13×
“In contrast to STAT3, which promotes MDSC accumulation, IRF8 deters PMN-MDSC accumulation.”
BackgroundInfluentialMyeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P., & Ostrand-Rosenberg, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2587 · Cited by 949 · cited 1×
“They sequester cysteine, another essential amino acid for T cell activation and function (78), polarize macrophages toward a tumor-promoting phenotype by downregulating macrophage production of the type 1 cytokine IL-12 (79, 80), inhibit NK-mediated tumor cell lysis (81), and induce and recruit T regulatory cells (82–…”
BackgroundSelf-citationCheng, P., Corzo, C. A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M. M., Ortiz, M., Nacken, W., Sorg, C., Vogl, T., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080132 · Cited by 902 · cited 2×
“It also induces S100A8/A9 expression, which drives the accumulation and differentiation of MDSC (64).”
BackgroundOvercoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860
Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor
Marigo, I., Bosio, E., Solito, S., Mesa, C., Fernandez, A., Dolcetti, L., Ugel, S., Sonda, N., Bicciato, S., Falisi, E., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.010 · Cited by 850
Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847
Self-citationThe Terminology Issue for Myeloid-Derived Suppressor Cells
Gabrilovich, D. I., Bronte, V., Chen, S.-H., Colombo, M. P., Ochoa, A., Ostrand-Rosenberg, S., & Schreiber, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3037 · Cited by 835 · cited 1×
“T he termmyeloid-derived suppressor cells (MDSC) was coined in 2007 to encompass a collection of nonmacrophage cells of myeloid origin that have potent immune-suppressive activity and are phenotypically characterized by a constellation of markers, none of which are unique to MDSC (1).”
BackgroundSelf-citationTu, S., Bhagat, G., Cui, G., Takaishi, S., Kurt-Jones, E. A., Rickman, B., Betz, K. S., Penz-Oesterreicher, M., Bjorkdahl, O., Fox, J. G., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.011 · Cited by 813
Condamine, T., Dominguez, G. A., Youn, J.-I., Kossenkov, A. V., Mony, S., Alicea-Torres, K., Tcyganov, E., Hashimoto, A., Nefedova, Y., Lin, C., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8943 · Cited by 789 · cited 1×
“For example, human neutrophils undergoing endoplasmic reticulum (ER) stress, as occurs within solid tumors, become immune-suppressive PMN-MDSC and express the lectin-type oxidized low-density lipoprotein receptor 1, OLR1 (33).”
BackgroundModulation of the antitumor immune response by complement
Markiewski, M. M., DeAngelis, R. A., Benencia, F., Ricklin-Lichtsteiner, S. K., Koutoulaki, A., Gerard, C., Coukos, G., & Lambris, J. D. (2008) · Nature Immunology · doi:10.1038/ni.1655 · Cited by 778 · cited 1×
“Tumor progression has been demonstrated in mice carrying TC-1 cervical carcinoma to be reduced after knockout of complement proteins C3 or C4, and complement component C5a was found to drive accumulation of MDSC (68).”
BackgroundMechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells
Corzo, C. A., Cotter, M. J., Cheng, P., Cheng, F., Kusmartsev, S., Sotomayor, E., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900092 · Cited by 763 · cited 1×
“MDSC that are deficient for gp91 lack suppressive activity and differentiate to DC and macrophages (100).”
BackgroundProstaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells
Sinha, P., Clements, V. K., Fulton, A. M., & Ostrand-Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4174 · Cited by 755
Self-citationTumor-Derived Exosomes and Their Role in Cancer Progression
(2016) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2015.12.005 · Cited by 755 · cited 1×
“Many of these vesicles contribute to the immune suppression common in cancer patients (117, 118), and in mouse models,”
BackgroundProinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
Sinha, P., Okoro, C., Foell, D., Freeze, H. H., Ostrand-Rosenberg, S., & Srikrishna, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4666 · Cited by 725 · cited 5×
“E-mail address: srosenbe@umbc.edu Abbreviations used in this article: Arg1, arginase 1; CHOP, C/EBP homologous protein; DC, dendritic cell; ER, endoplasmic reticulum; HDAC11, histone deacetylase 11; HMGB1, high mobility group box protein 1; IRF8, IFN-inducible regulatory factor 8; MDSC, myeloid-derived suppressor cell…”
BackgroundInfluentialSelf-citationKim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
Serafini, P., Mgebroff, S., Noonan, K., & Borrello, I. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6621 · Cited by 673
Doedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., Coussens, L. M., Karin, M., Goldrath, A. W., & Johnson, R. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1439 · Cited by 652 · cited 14×
“However, once in the tumor microenvironment most M-MDSC differentiate into immune-suppressive tumor-associated macrophages (35, 36).”
BackgroundInfluentialThe CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications
Chao, M. P., Weissman, I. L., & Majeti, R. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.01.010 · Cited by 649
Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., & Rivoltini, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5829 · Cited by 647 · cited 1×
“GM-CSF and G-CSF, important growth factors that regulate myelopoiesis, also drive the accumulation and suppressive function of MDSC in both mice (42–45) and patients (46) with cancer.”
BackgroundBunt, S. K., Yang, L., Sinha, P., Clements, V. K., Leips, J., & Ostrand-Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2354 · Cited by 633 · cited 2×
“induction is restored in IL-1R–deficient mice by provision of IL-6 (49).”
BackgroundSelf-citationArginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma
Rodriguez, P. C., Hernandez, C. P., Quiceno, D., Dubinett, S. M., Zabaleta, J., Ochoa, J. B., Gilbert, J., & Ochoa, A. C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050715 · Cited by 609 · cited 11×
“Inhibition of semaphorin 4D in the supernatants of cultured head and neck squamous cell carcinoma cells resulted in decreased levels of MDSC with reduced content of Arg1, TGF-b, and IL-10, and concurrent restoration of T cell activation.”
BackgroundInfluentialWu, P., Wu, D., Ni, C., Ye, J., Chen, W., Hu, G., Wang, Z., Wang, C., Zhang, Z., Xia, W., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.013 · Cited by 608
Induction of myeloid‐derived suppressor cells by tumor exosomes
Xiang, X., Poliakov, A., Liu, C., Liu, Y., Deng, Z., Wang, J., Cheng, Z., Shah, S. V., Wang, G., Zhang, L., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24249 · Cited by 598 · cited 1×
“tumor-derived exosomes have been shown to induce MDSC (119).”
BackgroundDolcetti, L., Peranzoni, E., Ugel, S., Marigo, I., Fernandez Gomez, A., Mesa, C., Geilich, M., Winkels, G., Traggiai, E., Casati, A., et al. (2010) · European Journal of Immunology · doi:10.1002/eji.200939903 · Cited by 569
Exosomes and tumor-mediated immune suppression
Whiteside, T. L. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81136 · Cited by 569 · cited 1×
“Many of these vesicles contribute to the immune suppression common in cancer patients (117, 118), and in mouse models,”
BackgroundMeyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1508-5 · Cited by 560
Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression
Bunt, S. K., Sinha, P., Clements, V. K., Leips, J., & Ostrand-Rosenberg, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.284 · Cited by 539
Self-citationBronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P., & Zanovello, P. (2000) · Blood · doi:10.1182/blood.v96.12.3838 · Cited by 527
Serafini, P., Carbley, R., Noonan, K. A., Tan, G., Bronte, V., & Borrello, I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0757 · Cited by 523
Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
Condamine, T., Ramachandran, I., Youn, J.-I., & Gabrilovich, D. I. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051013-052304 · Cited by 521
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Ostrand-Rosenberg, S. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0855-8 · Cited by 521 · cited 1×
“They sequester cysteine, another essential amino acid for T cell activation and function (78), polarize macrophages toward a tumor-promoting phenotype by downregulating macrophage production of the type 1 cytokine IL-12 (79, 80), inhibit NK-mediated tumor cell lysis (81), and induce and recruit T regulatory cells (82–…”
BackgroundSelf-citationYoun, J.-I., Collazo, M., Shalova, I. N., Biswas, S. K., & Gabrilovich, D. I. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0311177 · Cited by 510 · cited 1×
“Similarly, tumor-induced MDSC from C57BL/6 mice express CD115 and CD224, whereas neutrophils express neither of these plasma membrane molecules (34).”
BackgroundXin, H., Zhang, C., Herrmann, A., Du, Y., Figlin, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4323 · Cited by 504 · cited 1×
“It facilitates the survival of both mouse and human MDSC by upregulating the proliferation gene cyclin D1 and the antiapoptotic genes Bcl-xl and c-myc (98, 99).”
BackgroundObermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R. P., & Kalinski, P. (2011) · Blood · doi:10.1182/blood-2011-07-365825 · Cited by 497 · cited 1×
“PGE2 also drives the differentiation of MDSC from human hematopoietic stem cells (58), and for M-MDSC the induction is via the p38MAPK/ERK pathway (59, 60).”
BackgroundShojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902280106 · Cited by 471
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., & Gabrilovich, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.464 · Cited by 464 · cited 1×
“Early studies identified STAT3 as a key player in the accumulation of mouse MDSC (92).”
BackgroundSchlecker, E., Stojanovic, A., Eisen, C., Quack, C., Falk, C. S., Umansky, V., & Cerwenka, A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201018 · Cited by 438
Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells
Hanson, E. M., Clements, V. K., Sinha, P., Ilkovitch, D., & Ostrand-Rosenberg, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804253 · Cited by 427 · cited 1×
“function via a systemic mechanism involving MDSCmediated downregulation of L-selectin (CD62L) on circulating naive T cells (85).”
Self-citationCui, T. X., Kryczek, I., Zhao, L., Zhao, E., Kuick, R., Roh, M. H., Vatan, L., Szeliga, W., Mao, Y., Thomas, D. G., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.025 · Cited by 427
Bronte, V., Chappell, D. B., Apolloni, E., Cabrelle, A., Wang, M., Hwu, P., & Restifo, N. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5728 · Cited by 405
Myeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 386 · cited 1×
“As investigators became more aware of MDSC and tested for them in both cancer patients and mice with tumors, MDSC were increasingly recognized as a major spoiler of antitumor immunity because they accumulate in virtually all individuals with cancer (13, 14).”
BackgroundTNF signaling drives myeloid-derived suppressor cell accumulation
Zhao, X., Rong, L., Zhao, X., Li, X., Liu, X., Deng, J., Wu, H., Xu, X., Erben, U., Wu, P., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64115 · Cited by 378 · cited 1×
“TNF-a, another potent proinflammatory mediator that is commonly found in the tumor microenvironment, also increases the quantity and suppressive activity of MDSC (52).”
BackgroundPillay, J., Tak, T., Kamp, V. M., & Koenderman, L. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1286-4 · Cited by 375
Dumitru, C. A., Moses, K., Trellakis, S., Lang, S., & Brandau, S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1294-5 · Cited by 374
Transcriptional regulation of myeloid-derived suppressor cells
Condamine, T., Mastio, J., & Gabrilovich, D. I. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4ri0515-204r · Cited by 372 · cited 1×
“A more in-depth description can be found in a recent review (91).”
BackgroundTumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice
Lu, T., Ramakrishnan, R., Altiok, S., Youn, J.-I., Cheng, P., Celis, E., Pisarev, V., Sherman, S., Sporn, M. B., & Gabrilovich, D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45862 · Cited by 367 · cited 1×
“Peroxynitrite released by MDSC nitrates the TcR and MHC class I, thereby perturbing T cell recognition and preventing both T cell activation and T cell function (101, 102).”
BackgroundER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
Condamine, T., Kumar, V., Ramachandran, I. R., Youn, J.-I., Celis, E., Finnberg, N., El-Deiry, W. S., Winograd, R., Vonderheide, R. H., English, N. R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74056 · Cited by 365 · cited 1×
“MDSC of both tumor-bearing mice and cancer patients contain elevated levels of C/EBP homologous protein (CHOP), an indicator of ER stress (109), and induction of ER stress in tumor-bearing mice increased the levels of tumor-infiltrating MDSC and increased their suppressive potency by upregulating Arg1 and inducible NO…”
BackgroundTumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression
Mishalian, I., Bayuh, R., Levy, L., Zolotarov, L., Michaeli, J., & Fridlender, Z. G. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1476-9 · Cited by 356 · cited 1×
“The latter have been termed N2 neutrophils, whereas the former are N1 neutrophils (23, 24).”
BackgroundMeyer, C., Sevko, A., Ramacher, M., Bazhin, A. V., Falk, C. S., Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108121108 · Cited by 346
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis
Waight, J. D., Netherby, C., Hensen, M. L., Miller, A., Hu, Q., Liu, S., Bogner, P. N., Farren, M. R., Lee, K. P., Liu, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68189 · Cited by 323 · cited 1×
“As a result, IRF8-deficient mice have high levels of PMN-MDSC (103, 104), and overexpression of IRF8 in the myeloid lineage reduces MDSC accumulation (105, 106).”
BackgroundElkabets, M., Ribeiro, V. S. G., Dinarello, C. A., Ostrand‐Rosenberg, S., Di Santo, J. P., Apte, R. N., & Vosshenrich, C. A. J. (2010) · European Journal of Immunology · doi:10.1002/eji.201041037 · Cited by 319
Self-citationNefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S. M., & Gabrilovich, D. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0529 · Cited by 318 · cited 1×
“It facilitates the survival of both mouse and human MDSC by upregulating the proliferation gene cyclin D1 and the antiapoptotic genes Bcl-xl and c-myc (98, 99).”
BackgroundSinha, P., Clements, V. K., & Ostrand-Rosenberg, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0045 · Cited by 317
Self-citationBronte, V., Wang, M., Overwijk, W. W., Surman, D. R., Pericle, F., Rosenberg, S. A., & Restifo, N. P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5313 · Cited by 312
Fridlender, Z. G., Sun, J., Mishalian, I., Singhal, S., Cheng, G., Kapoor, V., Horng, W., Fridlender, G., Bayuh, R., Worthen, G. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031524 · Cited by 311 · cited 1×
“Although neutrophils lack immune-suppressive activity, their mRNA repertoire is more similar to PMN-MDSC, whereas the transcriptome of tumor-associated neutrophils and PMN-MDSC are less related (27).”
BackgroundSade-Feldman, M., Kanterman, J., Ish-Shalom, E., Elnekave, M., Horwitz, E., & Baniyash, M. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.007 · Cited by 307 · cited 5×
“E-mail address: srosenbe@umbc.edu Abbreviations used in this article: Arg1, arginase 1; CHOP, C/EBP homologous protein; DC, dendritic cell; ER, endoplasmic reticulum; HDAC11, histone deacetylase 11; HMGB1, high mobility group box protein 1; IRF8, IFN-inducible regulatory factor 8; MDSC, myeloid-derived suppressor cell…”
BackgroundInfluentialHuman neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells
Moses, K., & Brandau, S. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.018 · Cited by 305
Ko, J. S., Rayman, P., Ireland, J., Swaidani, S., Li, G., Bunting, K. D., Rini, B., Finke, J. H., & Cohen, P. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3278 · Cited by 296
Immunomonitoring and prognostic relevance of neutrophils in clinical trials
Donskov, F. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.02.001 · Cited by 293
Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C. A., Voronov, E., & Apte, R. N. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.8200 · Cited by 290
Bunt, S. K., Clements, V. K., Hanson, E. M., Sinha, P., & Ostrand-Rosenberg, S. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0708446 · Cited by 277
Self-citationKusmartsev, S., Eruslanov, E., Kübler, H., Tseng, T., Sakai, Y., Su, Z., Kaliberov, S., Heiser, A., Rosser, C., Dahm, P., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.346 · Cited by 276
Mao, Y., Sarhan, D., Steven, A., Seliger, B., Kiessling, R., & Lundqvist, A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0635 · Cited by 274 · cited 1×
“PGE2 also drives the differentiation of MDSC from human hematopoietic stem cells (58), and for M-MDSC the induction is via the p38MAPK/ERK pathway (59, 60).”
BackgroundPeng, D., Tanikawa, T., Li, W., Zhao, L., Vatan, L., Szeliga, W., Wan, S., Wei, S., Wang, Y., Liu, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2528 · Cited by 274 · cited 1×
“cancer cells, and by their production of NO, which activates the Notch pathway and sustains STAT3 activation (88).”
BackgroundThevenot, P. T., Sierra, R. A., Raber, P. L., Al-Khami, A. A., Trillo-Tinoco, J., Zarreii, P., Ochoa, A. C., Cui, Y., Del Valle, L., & Rodriguez, P. C. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.015 · Cited by 254 · cited 1×
“APCs in CHOP-deficient mice, indicating that CHOP is a positive regulator of MDSC (111).”
BackgroundOtvos, B., Silver, D. J., Mulkearns-Hubert, E. E., Alvarado, A. G., Turaga, S. M., Sorensen, M. D., Rayman, P., Flavahan, W. A., Hale, J. S., Stoltz, K., et al. (2016) · Stem Cells · doi:10.1002/stem.2393 · Cited by 245
Parker, K. H., Sinha, P., Horn, L. A., Clements, V. K., Yang, H., Li, J., Tracey, K. J., & Ostrand-Rosenberg, S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2347 · Cited by 241 · cited 1×
“MDSC in the blood have a default autophagic phenotype, and tumor-infiltrating MDSC are more autophagic due to the inflammatory tumor microenvironment (71).”
BackgroundSelf-citationStrober, S. (1984) · Annual Review of Immunology · doi:10.1146/annurev.iy.02.040184.001251 · Cited by 222
Contribution of MyD88 to the Tumor Exosome-Mediated Induction of Myeloid Derived Suppressor Cells
Liu, Y., Xiang, X., Zhuang, X., Zhang, S., Liu, C., Cheng, Z., Michalek, S., Grizzle, W., & Zhang, H.-G. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090777 · Cited by 218
Svoronos, N., Perales-Puchalt, A., Allegrezza, M. J., Rutkowski, M. R., Payne, K. K., Tesone, A. J., Nguyen, J. M., Curiel, T. J., Cadungog, M. G., Singhal, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0502 · Cited by 217 · cited 1×
“In mouse tumor models in which the tumor cells are nonresponsive to estrogen, estrogen has been shown to dysregulate myelopoiesis and drive the accumulation and suppressive activity of MDSC (67).”
BackgroundMorales, J. K., Kmieciak, M., Knutson, K. L., Bear, H. D., & Manjili, M. H. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0622-8 · Cited by 214
Mandruzzato, S., Brandau, S., Britten, C. M., Bronte, V., Damuzzo, V., Gouttefangeas, C., Maurer, D., Ottensmeier, C., van der Burg, S. H., Welters, M. J. P., et al. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1782-5 · Cited by 202 · cited 1×
“An international consortium of 23 laboratories has also been organized to test human MDSC with the goal of harmonizing staining and gating procedures for analysis of human MDSC (16).”
BackgroundRORC1 Regulates Tumor-Promoting “Emergency” Granulo-Monocytopoiesis
Strauss, L., Sangaletti, S., Consonni, F. M., Szebeni, G., Morlacchi, S., Totaro, M. G., Porta, C., Anselmo, A., Tartari, S., Doni, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.006 · Cited by 199
Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples
Kotsakis, A., Harasymczuk, M., Schilling, B., Georgoulias, V., Argiris, A., & Whiteside, T. L. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.04.004 · Cited by 199 · cited 2×
“PMN-MDSC are particularly sensitive to cryopreservation (18, 19).”
BackgroundMao, Y., Poschke, I., Wennerberg, E., Pico de Coaña, Y., Egyhazi Brage, S., Schultz, I., Hansson, J., Masucci, G., Lundqvist, A., & Kiessling, R. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4115 · Cited by 192 · cited 1×
“PGE2 also drives the differentiation of MDSC from human hematopoietic stem cells (58), and for M-MDSC the induction is via the p38MAPK/ERK pathway (59, 60).”
BackgroundBeury, D. W., Parker, K. H., Nyandjo, M., Sinha, P., Carter, K. A., & Ostrand-Rosenberg, S. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0414-210r · Cited by 183 · cited 1×
“This cross-talk reciprocally molds the phenotype and function of both MDSC and host tumor-infiltrating cells (37).”
BackgroundSelf-citationClements, V. K., Long, T., Long, R., Figley, C., Smith, D. M. C., & Ostrand-Rosenberg, S. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.4hi0517-210r · Cited by 171 · cited 1×
“diet, situations in which low-grade inflammation is chronic (132, 133).”
Self-citationXia, S., Sha, H., Yang, L., Ji, Y., Ostrand-Rosenberg, S., & Qi, L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.237123 · Cited by 169 · cited 1×
“diet, situations in which low-grade inflammation is chronic (132, 133).”
BackgroundSelf-citationEzernitchi, A. V., Vaknin, I., Cohen-Daniel, L., Levy, O., Manaster, E., Halabi, A., Pikarsky, E., Shapira, L., & Baniyash, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4763 · Cited by 169
Protumor and antitumor functions of neutrophil granulocytes
Brandau, S., Dumitru, C. A., & Lang, S. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-012-0344-6 · Cited by 158
Köstlin, N., Kugel, H., Spring, B., Leiber, A., Marmé, A., Henes, M., Rieber, N. P., Hartl, D., Poets, C. F., & Gille, C. (2014) · European Journal of Immunology · doi:10.1002/eji.201344200 · Cited by 157 · cited 1×
“toward a type 2 cytokine response (129, 130).”
BackgroundExosomes from Myeloid-Derived Suppressor Cells Carry Biologically Active Proteins
Burke, M., Choksawangkarn, W., Edwards, N., Ostrand-Rosenberg, S., & Fenselau, C. (2014) · Journal of Proteome Research · doi:10.1021/pr400879c · Cited by 157 · cited 2×
“Both activities were mediated by S100A8/A9 (120).”
BackgroundSelf-citationSinha, P., Chornoguz, O., Clements, V. K., Artemenko, K. A., Zubarev, R. A., & Ostrand-Rosenberg, S. (2011) · Blood · doi:10.1182/blood-2010-11-321752 · Cited by 154 · cited 1×
“network proteins in MDSC induced under a heightened inflammatory milieu, and cellular studies with Fas agonists demonstrated that inflammation increases MDSC resistance to Fas-mediated apoptosis (29, 69, 70).”
BackgroundSelf-citationChemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion
Talmadge, J. E., Hood, K. C., Zobel, L., Shafer, L. R., Coles, M., & Tóth, B. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.09.021 · Cited by 139
TGF-β Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms
Novitskiy, S. V., Pickup, M. W., Gorska, A. E., Owens, P., Chytil, A., Aakre, M., Wu, H., Shyr, Y., & Moses, H. L. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0100 · Cited by 136 · cited 2×
“IL-17 is another cytokine that is present in the environment of many solid tumors and regulates the accumulation and suppressive activity of MDSC. Studies in IL-17–deficient tumor-bearing mice demonstrated that IL-17 increases intratumoral levels of MDSC and raises their intracellular levels of Arg1, cyclooxygenase 2,…”
BackgroundTumor-induced myeloid dysfunction and its implications for cancer immunotherapy
Messmer, M. N., Netherby, C. S., Banik, D., & Abrams, S. I. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1639-3 · Cited by 120 · cited 1×
“As investigators became more aware of MDSC and tested for them in both cancer patients and mice with tumors, MDSC were increasingly recognized as a major spoiler of antitumor immunity because they accumulate in virtually all individuals with cancer (13, 14).”
BackgroundKöstlin, N., Hofstädter, K., Ostermeir, A., Spring, B., Leiber, A., Haen, S., Abele, H., Bauer, P., Pollheimer, J., Hartl, D., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500340 · Cited by 120 · cited 1×
“toward a type 2 cytokine response (129, 130).”
BackgroundKu, A. W., Muhitch, J. B., Powers, C. A., Diehl, M. R., Kim, M., Fisher, D. T., Sharda, A. P., Clements, V. K., O’Loughlin, K. L., Minderman, H., et al. (2016) · eLife · doi:10.7554/elife.17375 · Cited by 120 · cited 1×
“Recent in vivo imaging studies have confirmed that while circulating in the blood, MDSC downregulate T cell expression of Lselectin, and this downregulation prevents naive T cells from entering lymph nodes and becoming activated (86).”
BackgroundSelf-citationSahakian, E., Powers, J. J., Chen, J., Deng, S. L., Cheng, F., Distler, A., Woods, D. M., Rock-Klotz, J., Sodre, A. L., Youn, J.-I., et al. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2014.08.002 · Cited by 119 · cited 1×
“pressive MDSC, suggesting that HDAC11 is a negative regulator for the development of MDSC (116).”
BackgroundOstrand‐Rosenberg, S., Sinha, P., Figley, C., Long, R., Park, D., Carter, D., & Clements, V. K. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.1hi1016-306rr · Cited by 113 · cited 1×
“are not merely bystanders or passenger cells has been obtained in mice (131).”
BackgroundSelf-citationMyeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2
Beury, D. W., Carter, K. A., Nelson, C., Sinha, P., Hanson, E., Nyandjo, M., Fitzgerald, P. J., Majeed, A., Wali, N., & Ostrand-Rosenberg, S. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501785 · Cited by 111 · cited 1×
“Interestingly, these studies also demonstrated that there is a strong homeostatic regulation of MDSC and that when the half-life of tumor-infiltrating MDSC is decreased, there is a compensatory increase in the rate of MDSC production in the bone marrow so that steadystate levels of MDSC in the blood are maintained (72…”
BackgroundSelf-citationGeis-Asteggiante, L., Belew, A. T., Clements, V. K., Edwards, N. J., Ostrand-Rosenberg, S., El-Sayed, N. M., & Fenselau, C. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00646 · Cited by 104 · cited 1×
“were used in an integrated study of proteins, mRNA, and miRNA carried in exosomes shed by MDSC (125).”
MethodSelf-citationLee, B.-R., Chang, S.-Y., Hong, E.-H., Kwon, B.-E., Kim, H. M., Kim, Y.-J., Lee, J., Cho, H.-J., Cheon, J.-H., & Ko, H.-J. (2014) · Oncotarget · doi:10.18632/oncotarget.2589 · Cited by 98
Trellakis, S., Bruderek, K., Hütte, J., Elian, M., Hoffmann, T. K., Lang, S., & Brandau, S. (2013) · Innate Immunity · doi:10.1177/1753425912463618 · Cited by 96 · cited 1×
“PMN-MDSC are particularly sensitive to cryopreservation (18, 19).”
BackgroundDevelopment of splenic natural suppressor (NS) cells in ehrlich tumor‐bearing mice
Subiza, J. L., Viñuela, J. E., Rodríguez, R., Gil, J., Figueredo, M. A., & de la Concha, E. G. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910440220 · Cited by 80
Ortiz, M. L., Kumar, V., Martner, A., Mony, S., Donthireddy, L., Condamine, T., Seykora, J., Knight, S. C., Malietzis, G., Lee, G. H., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140835 · Cited by 80 · cited 1×
“Depletion of either CCL4 or the CD4 T cells prevented the effect, demonstrating that MDSC indirectly drive epidermal carcinogenesis (87).”
BackgroundNetherby, C. S., Messmer, M. N., Burkard-Mandel, L., Colligan, S., Miller, A., Cortes Gomez, E., Wang, J., Nemeth, M. J., & Abrams, S. I. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601722 · Cited by 77 · cited 1×
“As a result, IRF8-deficient mice have high levels of PMN-MDSC (103, 104), and overexpression of IRF8 in the myeloid lineage reduces MDSC accumulation (105, 106).”
BackgroundSurface Glycoproteins of Exosomes Shed by Myeloid-Derived Suppressor Cells Contribute to Function
Chauhan, S., Danielson, S., Clements, V., Edwards, N., Ostrand-Rosenberg, S., & Fenselau, C. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00811 · Cited by 74 · cited 1×
“In vitro studies demonstrated that exosomal CD47 served as a powerful chemotactic signal for parental MDSC with thrombospondin-1 being the predominant ligand and SIRPa playing a lesser role (123).”
BackgroundSelf-citationOstrand‐Rosenberg, S., Sinha, P., Chornoguz, O., & Ecker, C. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1269-6 · Cited by 71 · cited 1×
“network proteins in MDSC induced under a heightened inflammatory milieu, and cellular studies with Fas agonists demonstrated that inflammation increases MDSC resistance to Fas-mediated apoptosis (29, 69, 70).”
BackgroundSelf-citationChornoguz, O., Grmai, L., Sinha, P., Artemenko, K. A., Zubarev, R. A., & Ostrand-Rosenberg, S. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.002980 · Cited by 69 · cited 1×
“network proteins in MDSC induced under a heightened inflammatory milieu, and cellular studies with Fas agonists demonstrated that inflammation increases MDSC resistance to Fas-mediated apoptosis (29, 69, 70).”
BackgroundSelf-citationHong, E., Chang, S., Lee, B., Kim, Y., Lee, J., Kang, C., Kweon, M., & Ko, H. (2012) · International Journal of Cancer · doi:10.1002/ijc.27974 · Cited by 68
Younis, R., Han, K., & Webb, T. (2016) · Journal of Immunology · doi:10.4049/jimmunol.1501293 · Cited by 67 · cited 1×
“Using head and neck squamous cell carcinoma cells, the induction of human MDSC has also been ascribed to semaphorin 4D, a proangiogenic cytokine that is produced by several types of cancers (66).”
BackgroundAbad, C., Nobuta, H., Li, J., Kasai, A., Yong, W. H., & Waschek, J. A. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012531 · Cited by 63
Yuan, H., Cai, P., Li, Q., Wang, W., Sun, Y., Xu, Q., & Gu, Y. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.07.002 · Cited by 62
A core of kinase-regulated interactomes defines the neoplastic MDSC lineage
Gato, M., de Morentin, X. M., Blanco‐Luquin, I., Fernández‐Irigoyen, J., Zudaire, I., Liechtenstein, T., Arasanz, H., Lozano, T., Casares, N., Chaikuad, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4746 · Cited by 61
Ubiquitinated Proteins in Exosomes Secreted by Myeloid-Derived Suppressor Cells
Burke, M. C., Oei, M. S., Edwards, N. J., Ostrand-Rosenberg, S., & Fenselau, C. (2014) · Journal of Proteome Research · doi:10.1021/pr500854x · Cited by 55 · cited 1×
“HMGB1 were among the ubiquitinated species detected (122).”
BackgroundSelf-citationInterferon regulatory factor‐8 modulates the development of tumour‐induced CD11b+Gr‐1+ myeloid cells
Stewart, T. J., Greeneltch, K. M., Reid, J. E., Liewehr, D. J., Steinberg, S. M., Liu, K., & Abrams, S. I. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00685.x · Cited by 52 · cited 1×
“As a result, IRF8-deficient mice have high levels of PMN-MDSC (103, 104), and overexpression of IRF8 in the myeloid lineage reduces MDSC accumulation (105, 106).”
BackgroundNam, S., Kang, K., Cha, J. S., Kim, J. W., Lee, H. G., Kim, Y., Yang, Y., Lee, M.-S., & Lim, J.-S. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.1a0215-068rr · Cited by 50
Young, M. R. I., Kolesiak, K., Wright, M. A., & Gabrilovich, D. I. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006708607666 · Cited by 46
Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease
Netherby, C. S., & Abrams, S. I. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1963-5 · Cited by 41 · cited 1×
“As a result, IRF8-deficient mice have high levels of PMN-MDSC (103, 104), and overexpression of IRF8 in the myeloid lineage reduces MDSC accumulation (105, 106).”
BackgroundYoung, M. R., Aquino, S., & Young, M. E. (1989) · Journal of Leukocyte Biology · doi:10.1002/jlb.45.3.262 · Cited by 40
Drafting the proteome landscape of myeloid‐derived suppressor cells
Gato, M., Blanco‐Luquin, I., Zudaire, M., de Morentin, X. M., Pérez‐Valderrama, E., Zabaleta, A., Kochan, G. T., Escors, D., Fernández‐Irigoyen, J., & Santamaría, E. (2015) · PROTEOMICS · doi:10.1002/pmic.201500229 · Cited by 34
Evaluation of Spectral Counting for Relative Quantitation of Proteoforms in Top-Down Proteomics
Geis‐Asteggiante, L., Ostrand‐Rosenberg, S., Fenselau, C., & Edwards, N. J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b02151 · Cited by 34 · cited 1×
“At the proteomic level, mass spectrometry studies also revealed that MDSC express a distinct profile (28–31), with S100A8 and S100A9 being prominently expressed by MDSC (28, 32).”
BackgroundSelf-citationChoi, K. L., Maier, T., Holda, J. H., & Claman, H. N. (1988) · Cellular Immunology · doi:10.1016/0008-8749(88)90297-3 · Cited by 20
Choksawangkarn, W., Graham, L. M., Burke, M. C., Lee, S. B., Ostrand‐Rosenberg, S., Fenselau, C., & Edwards, N. J. (2016) · PROTEOMICS · doi:10.1002/pmic.201500102 · Cited by 20 · cited 3×
“They are also present in the plasma membrane of tumor-induced mouse MDSC as shown by spectral counting and mass spectrometry (28).”
BackgroundSelf-citationAdams, K. R., Chauhan, S., Patel, D. B., Clements, V. K., Wang, Y., Jay, S. M., Edwards, N. J., Ostrand‐Rosenberg, S., & Fenselau, C. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00585 · Cited by 16
Self-citationImmune Suppressive Myeloid-Derived Suppressor Cells in Cancer
Ostrand‐Rosenberg, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.17015-8 · Cited by 4
Self-citationHigh fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells
Clements, V. K., Long, T., Long, R., Figley, C., Smith, D., & Ostrand‐Rosenberg, S. (2018) · Maryland Shared Open Access Repository (USMAI Consortium) · doi:10.13016/m2z02zb5k · Cited by 1
Self-citation
Research works printed but not linked: 1
- Geis-Asteggiante L 2017 Quantitative analysis of intact proteins and RNAs carried by immunosuppressive exosomes Ph.D. thesis University of Maryland
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538
Metadata
- Authors
- Ostrand-Rosenberg, S., & Fenselau, C.
- Affiliations
- Department of Biological Sciences, University of Maryland Baltimore County , Baltimore, MD 21250
- University of Maryland, College Park (US)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01
- Volume
- 200
- Issue
- 2
- Pages
- 422-431
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC5765878
- OpenAlex
- W2783633531
- Cited by
- 509
- References
- 135
- Citations by year
- 2026: 34 · 2025: 42 · 2024: 44 · 2023: 61 · 2022: 71 · 2021: 117 · 2020: 80 · 2019: 39 · 2018: 21
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Maryland Shared Open Access Repository (USMAI Consortium) (submittedVersion)
- Digital Repository at the University of Maryland (University of Maryland College Park)
- Funders
- National Institutes of Health (1s10od019938-01, RO1 GM021248)
- National Cancer Institute (R01CA084232, R01CA115880)
- National Institute of General Medical Sciences (R01GM021248)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- myeloid-derived suppressor cells, tumor immunosuppression, antitumor immunity, tumor microenvironment, pro-inflammatory mediators, neutrophils, cancer immunotherapy resistance, tumor progression
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Humans, Neoplasms, Phenotype, Cytokines, Disease Progression, Inflammation Mediators, Immunomodulation, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.